Senti Biosciences appoints Feng Hsiung to board, stockholders approve 4.3M share increase in equity plan

Senti Biosciences, Inc.

Feng Hsiung appointed to board as Class III director effective March 7, 2025; also joins audit committee.
Stockholders approved Amended 2022 Equity Incentive Plan adding 4,300,000 shares and extending term to 2035.
Board adopted Amended Inducement Plan reserving extra 500,000 shares for new-hire inducement grants.
Non-employee director compensation policy revised; each continuing director received 43,900-share option grant.
CEO Timothy Lu received contingent option for 1,927,073 shares and RSU for 642,358 shares.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Feng Hsiung

Class III Director

SNTI · Senti Biosciences, Inc.

Effective: 2025-03-07
Filed: March 10, 2025, 7:59 PM ET

On March 7, 2025, the Board of Directors (the “Board”) of Senti Biosciences, Inc. (the “Company”) approved the appointment of Feng Hsiung to the Board, pursuant to the terms of a letter agreement dated as of December 2, 2024, by and between the Company and Celadon Partners SPV 24.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Feng Hsiung was appointed as Class III Director at Senti Biosciences, Inc..

Action: appointed
Role: Class III Director

Exact text from the filing

On March 7, 2025, the Board of Directors (the “Board”) of Senti Biosciences, Inc. (the “Company”) approved the appointment of Feng Hsiung to the Board, pursuant to the terms of a letter agreement dated as of December 2, 2024, by and between the Company and Celadon Partners SPV 24.

View on SEC.gov

Senti Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001140361-25-007862

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.